NUCALA

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: 02c544b4edcdecd1
Drug Approval Canada Name: NUCALA
Product Name: NUCALA
Status: Marketed
Status Date: 2019-12-10
Original Market Date: 2019-12-10
Din: 02492997
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 90:28.00
Atc Original: R03DX09 MEPOLIZUMAB
Atc Name: r 03 dx 09
Aig Number: 0157630001
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

MEPOLIZUMAB

100 MG / ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

02c544b4edcdecd1

Type

Standard